{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"8.2","value":"3.4"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"6.4","value":"2.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"PFS is defined as the time from first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression based on the time of first documentation of disease progression per RECIST v1.1. Progression is defined using RECIST v1.1 as a 20% increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions or the appearance of one or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Ovarian Cancer (OC) received recommended phase 2 dose (RP2D) of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 2 OC: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) received RP2D of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set. Only those participants with data available at specified time point were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 54 months","title":"Phase 2: Progression Free Survival (PFS) as Measured by RECIST v1.1","type":"SECONDARY","unitOfMeasure":"Months"}